NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD

Bone Marrow Transplantation

Volumn 49, Issue 12, 2014, Pages 1513-1520

  Curtis, L M ^a   Grkovic, L ^a,b   Mitchell, S A ^c   Steinberg, S M ^a   Cowen, E W ^a   Datiles, M B ^d   Mays, J ^e   Bassim, C ^e   Joe, G ^c   Comis, L E ^c   Berger, A ^c   Avila, D ^a   Taylor, T ^a   Pulanic, D ^b   Cole, K ^a   Baruffaldi, J ^a   Fowler, D H ^a   Gress, R E ^a   Pavletic, S Z ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KBC Zagreb   (Croatia)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONCURRENT VALIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EOSINOPHIL COUNT; ERYTHEMA; EXERCISE TEST; FEMALE; GLOBAL SYMPTOM SEVERITY SCORE; GRIP STRENGTH; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KARNOFSKY PERFORMANCE STATUS; LEE SYMPTOM SCORE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NIH RESPONSE CRITERIA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM; SELF REPORT; SHORT FORM 36; SURVIVAL RATE; TREATMENT RESPONSE; WALKING;

EID: 85027950955     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.188     Document Type: Article

References (21)

1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233.
2. Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010; 28: 1888-1895.
3. Lee SJ. Have we made progress in the management of chronic graft-vs-host disease? Best Pract Res Clin Haematol 2010; 23: 529-535.
4. Flowers ME, Storer B, Carpenter P, Rezvani AR, Vigorito AC, Campregher PV et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 1380-1384.
5. Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17: 1-17.
6. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252-266.
7. Olivieri A, Cimminiello M, Corradini P, Mordini N, Fedele R, Selleri C et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 2013; 122: 4111-4118.
8. Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA et al. National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant 2013; 19: 632-639.
9. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
10. Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW et al. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia 2012; 26: 633-643.
11. Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 444-452.
12. Hollander M, Wolfe DA. Nonparametric statistical methods, 2nd edn (Wiley: New York, 1999.
13. Agresti A. Categorical data analysis, 1st edn. Wiley: New York, 1990.
14. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-735.
15. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444.
16. Preston CC, Colman AM. Optimal number of response categories in rating scales: reliability, validity, discriminating power, and respondent preferences. Acta Psychol (Amst) 2000; 104: 1-15.
17. Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology 2012; 119: 487-493.
18. Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219-1226.
19. Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 2012; 120: 2545-2552 quiz 2774.
20. Wiener L, Baird K, Crum C, Powers K, Carpenter P, Baker KS et al. Child and parent perspectives of the chronic graft-versus-host disease (cGVHD) symptom experience: a concept elicitation study. Support Care Cancer 2014; 22: 295-305.
21. Mitchell SA, Leidy NK, Mooney KH, Dudley WN, Beck SL, LaStayo PC et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 2010; 45: 762-769.